According to
reports, Australia Walter and Eliza Howe Institute (WEHI) and other
units of scientists for cancer, "tailor" made to order a new drug that
can contain cells called BCL-XL protein, this protein will promote cancer cell
survival, so many anti-cancer measures ineffective. The researchers
pointed out that this is the design of new anti-cancer drugs to an
important step. Related papers published online in "Nature Chemical
Biology" magazine. BCL-XL is a
pro-survival BCL-2 family of proteins in one, can prevent cell death.
And this drug called WEHI-539, specifically designed to work with BCL-XL
protein binding and curb its role in the ability to restore cell death.
Death and rid the body of abnormal cells that fight cancer development,
an important protective measures. However, in solid tumors, BCL-XL
overexpression often generate high levels of BCL-XL protein cause cancer
cells to become very long-lived, they are also associated with lung
cancer, stomach cancer, colon cancer and pancreatic cancer deterioration
related to the malignant Many cancer cells resistant to treatment, such
as chemotherapy.
BCL-XL contain apoptotic response can be improved, which may widely used in cancer therapy, and many do not contain pro-BCL-2 family. WEHI-539 is a specifically selective inhibitors of BCL-XL, the drug is expected toxicity to normal tissue damage is minimized.
WEHI-539 belongs to a class called "BH3 Class" chemicals, they can with BCL-XL and related binding proteins in the same area, which is a division of the Institute of Chemical Biology ACRF Guillaume Lai Sena and others with Roche's Genentech experts of a long-term research project achievements.
"We are very pleased to team developed a special compound containing BCL-XL, which is the study of the work of a peak. WEHI-539 is our chemists developed from scratch the first drugs, but also with the BCL- XL three-dimensional structure to build and improve drug design. "Lai Sena said that in the creation of new anti-cancer drugs may be on the road, the development of WEHI-539 is an important milestone. Although the use of WEHI-539 has not yet reached the optimal effect, but it is a valuable tool that can be used to BCL-XL features to distinguish their companions to a detailed analysis of BCL-XL to control cancer cells.
New anti-cancer drugs WEHI-539
From Australia Walter and Eliza Hall Institute of Medical Research, researchers developed a novel compound that can cause blocking one kind of cancer patients with poor response to treatment-related proteins. This new compound, called WEHI-539, will help cancer patients with chemotherapy.
BCL-XL protein expression in cancer cells with high levels of longer life, and high expression of this protein also associated with lung, stomach, colon and pancreatic cancer patients poorer prognosis.
In this article, Lessene same Dr. College ACRF Chemical Biology Department David Hua, and Peter Czabotar and others, to cooperate with Genentech, Inc., developed such a compound called WEHI-539.
Such compounds can bind to and block the protein BCL-XL features - prolong the life of cells, the body and the elimination of abnormal cell death is an important guarantee for the development of cancer cells. However, mutations in cancer tends to occur, which can bypass the cell death, which also reduces the effectiveness of chemotherapy and other cancer treatments.
BCL-XL contain apoptotic response can be improved, which may widely used in cancer therapy, and many do not contain pro-BCL-2 family. WEHI-539 is a specifically selective inhibitors of BCL-XL, the drug is expected toxicity to normal tissue damage is minimized.
WEHI-539 belongs to a class called "BH3 Class" chemicals, they can with BCL-XL and related binding proteins in the same area, which is a division of the Institute of Chemical Biology ACRF Guillaume Lai Sena and others with Roche's Genentech experts of a long-term research project achievements.
"We are very pleased to team developed a special compound containing BCL-XL, which is the study of the work of a peak. WEHI-539 is our chemists developed from scratch the first drugs, but also with the BCL- XL three-dimensional structure to build and improve drug design. "Lai Sena said that in the creation of new anti-cancer drugs may be on the road, the development of WEHI-539 is an important milestone. Although the use of WEHI-539 has not yet reached the optimal effect, but it is a valuable tool that can be used to BCL-XL features to distinguish their companions to a detailed analysis of BCL-XL to control cancer cells.
New anti-cancer drugs WEHI-539
From Australia Walter and Eliza Hall Institute of Medical Research, researchers developed a novel compound that can cause blocking one kind of cancer patients with poor response to treatment-related proteins. This new compound, called WEHI-539, will help cancer patients with chemotherapy.
BCL-XL protein expression in cancer cells with high levels of longer life, and high expression of this protein also associated with lung, stomach, colon and pancreatic cancer patients poorer prognosis.
In this article, Lessene same Dr. College ACRF Chemical Biology Department David Hua, and Peter Czabotar and others, to cooperate with Genentech, Inc., developed such a compound called WEHI-539.
Such compounds can bind to and block the protein BCL-XL features - prolong the life of cells, the body and the elimination of abnormal cell death is an important guarantee for the development of cancer cells. However, mutations in cancer tends to occur, which can bypass the cell death, which also reduces the effectiveness of chemotherapy and other cancer treatments.
Lessene PhD,
research WEHI-539 is for BCL-XL protein in cancer drug research is a
milestone, "WEHI-539, although not yet optimized for the patient,
but it can provide researchers with a very favorable research tool for
parsing BCL-XL how to control the cancer cells to survive, "he said.
WEHI-539 belongs to a class of chemicals called BH3 analogues, such substances can be bound to or associated proteins BCL-XL in the same area B on. Two BH3-mimetic called navitoclax (ABT-263) and ABT-199/GDC-0199, currently in clinical trials testing the efficacy of the treatment of cancer, especially for those in the blood and lymph cancers (leukemia and lymphatic tumors).
Lessene Dr., WEHI-539 is their ongoing research for many years to get results, "We are very pleased to see that this compound can specifically inhibit BCL-XL, which is the first one for the BCL-XL to establish and improve the three-dimensional structure design compounds. "
Cancer: a terrible mutated cells
Cancer is a variation of cells, pathogens produce cancer, cancer cells and normal cells, there is unlimited growth, transformation and transfer of three characteristics, and therefore difficult to eliminate.
Cancer cells by the "rebellion" in normal cells derived from, after many years to grow into tumors. In the process of cell differentiation "mutiny" cell detachment on track to set their own proliferation rate, accumulated to more than 1 billion we will detect. The proliferation rate of cells with doubling time calculation, a variable 2, 2 becomes 4, and so on. For example, gastric cancer, colon cancer, liver cancer, pancreatic cancer, esophageal average doubling time is 31 days; breast cancer doubling time more than 40 days. Because cancer cells continue to multiply, the more to the late development of cancer faster.
Cancer lurks outside itself can not overcome and reverse the factors that can not be excluded, which is its features, but also its shortcomings, it created instability.
Scientists pointed out that the cancer cells in the transfer process will encounter many difficulties, we must first go through dozens of variations, and to overcome the effect of cell adhesion was spun off and change shape through the dense connective tissue. Successful escape, and the cancer cells into the blood through the capillaries, where it may have been attacked leukocytes. The next cell will enter a new organ through capillaries (now known as "micro shift"). Here, the cancer is not friendly to the environment faces (called "micro-environment"), some cells die immediately, some died after split several times, and some remain dormant, the survival rate is only one of hundreds of millions of points. Surviving cancer cells can regenerate and colonization assays can be found in the "visible shift." With the development of metastases, it is crowding out the normal cells to destroy the organ function, and finally fatal.
WEHI-539 belongs to a class of chemicals called BH3 analogues, such substances can be bound to or associated proteins BCL-XL in the same area B on. Two BH3-mimetic called navitoclax (ABT-263) and ABT-199/GDC-0199, currently in clinical trials testing the efficacy of the treatment of cancer, especially for those in the blood and lymph cancers (leukemia and lymphatic tumors).
Lessene Dr., WEHI-539 is their ongoing research for many years to get results, "We are very pleased to see that this compound can specifically inhibit BCL-XL, which is the first one for the BCL-XL to establish and improve the three-dimensional structure design compounds. "
Cancer: a terrible mutated cells
Cancer is a variation of cells, pathogens produce cancer, cancer cells and normal cells, there is unlimited growth, transformation and transfer of three characteristics, and therefore difficult to eliminate.
Cancer cells by the "rebellion" in normal cells derived from, after many years to grow into tumors. In the process of cell differentiation "mutiny" cell detachment on track to set their own proliferation rate, accumulated to more than 1 billion we will detect. The proliferation rate of cells with doubling time calculation, a variable 2, 2 becomes 4, and so on. For example, gastric cancer, colon cancer, liver cancer, pancreatic cancer, esophageal average doubling time is 31 days; breast cancer doubling time more than 40 days. Because cancer cells continue to multiply, the more to the late development of cancer faster.
Cancer lurks outside itself can not overcome and reverse the factors that can not be excluded, which is its features, but also its shortcomings, it created instability.
Scientists pointed out that the cancer cells in the transfer process will encounter many difficulties, we must first go through dozens of variations, and to overcome the effect of cell adhesion was spun off and change shape through the dense connective tissue. Successful escape, and the cancer cells into the blood through the capillaries, where it may have been attacked leukocytes. The next cell will enter a new organ through capillaries (now known as "micro shift"). Here, the cancer is not friendly to the environment faces (called "micro-environment"), some cells die immediately, some died after split several times, and some remain dormant, the survival rate is only one of hundreds of millions of points. Surviving cancer cells can regenerate and colonization assays can be found in the "visible shift." With the development of metastases, it is crowding out the normal cells to destroy the organ function, and finally fatal.
No comments:
Post a Comment